Q4 2024 Krishna Institute of Medical Sciences Ltd Earnings Call Transcript
Key Points
- Gross revenue increased by 9.8% year-on-year and 4.7% quarter-on-quarter, reaching INR6,376 million.
- EBITDA grew by 8.3% quarter-on-quarter, despite a year-on-year decline.
- Operational highlights show growth in both IP and OP volumes, with OP volumes increasing by 7.9% year-on-year.
- KIMS entered into a definitive agreement for a new hospital in Thane, Mumbai, expected to be operational by Q4 2025.
- The company has seen positive developments in its Sunshine Hospital, with good consultant joinings and expected EBITDA growth.
- EBITDA margin declined to 25.5% in Q4 FY24 from 28.9% in Q4 FY23.
- PAT decreased to INR716 million in Q4 FY24 from INR987 million in Q4 FY23.
- There was a one-time expense of INR10 crore, impacting EBITDA negatively.
- Depreciation costs increased significantly from INR35 crores to INR46 crores due to new operational facilities.
- There is muted growth in Telangana due to bed capacity issues and delayed doctor engagements.
Ladies and gentlemen, good day, and welcome to KIMS Hospital's Q4 FY24 earnings conference call hosted by IIFL Securities Limited. (Operator Instructions)
Please note that this conference is being recorded.
I now hand the conference over to Mr. Rahul Jeewani from IIFL Securities Limited. Thank you, and over to you, sir.
Thank you. Good morning, everyone. I'm Rahul from IIFL Institutional Equities. On behalf of IIFL, I welcome you to the quarter four earnings conference call of KIMS Hospitals. From KIMS, we have with us Dr. Bhaskara Rao Bollineni, Founder and Managing Director; Dr. Abhinay Bollineni, Executive Director and CEO; and Mr. Sachin Salvi, CFO.
Over to you, sir, for your opening comments.
Good morning, all of you. A hearty welcome to all of you. I'm happy to share with you that this is a landmark year in the growing trajectory of KIMS
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
